net income -$111.3M. Kailera Therapeutics posts company with cash runway into mid-2028

Filed August 12, 2026 · Period ending June 30, 2026 · ~2 min read

Key Changes

• high

  Completed $718.8M IPO in April 2026 (44.9M shares at $16.00), netting $662M after fees; cash/securities total $1.2B as of June 30, funding operations into mid-2028.

  Notes: IPO completion view on EDGAR →
• high

  Q2 2026 net loss $111M (vs. $29M prior year) on Phase 3 trial ramp for lead candidate ribupatide injection; H1 2026 net loss $190M, accumulated deficit $559M.

  MD&A: Q2 2026 operating results verify on EDGAR →
• high

  Hengrui reported positive Phase 3 topline data for ribupatide injection in type 2 diabetes (China): 4mg dose achieved 2.67%-2.78% HbA1c reduction, superior to semaglutide 1mg in head-to-head trial.

  MD&A: Phase 3 trial results verify on EDGAR →